DAPPA: Diagnostic Accuracy in Pre-Eclampsia using Proteinuria Assessment

DAPPA: Diagnostic Accuracy in Pre-Eclampsia using Proteinuria Assessment

MedSciNet has implemented and launched an online application for DAPPA, a multi-centre diagnostic accuracy study of spot protein creatinine ratio (SPCr) and spot albumin creatinine ratio (SACr) compared with 24 hour urine protein measurement at different thresholds in diagnosing and predicting severe pre-eclampsia.

Pre-eclampsia is a disorder of pregnancy indicated by both high blood pressure and proteinuria. It requires complex treatments leading to large health care costs. Determining the most appropriate method and threshold for measuring abnormal amounts of proteinuria that predicts pre-eclampsia and its severity is needed to provide pre-eclampsia patients with the best possible care while reducing unnecessary intervention in those without pre-eclampsia.

The DAPPA study is aimed at determining the method of measurement and the diagnostic thresholds that are most accurate in predicting not just pre-eclampsia but the clinical significant outcomes which will help inform clinicians on the correct clinical management of gestational hypertensive disorders during pregnancy.

The DAPPA study is sponsored by Newcastle Hospitals NHS Foundation Trust (UK) and funded by NIHR Health Technology Assessment Programme (UK).